MSD has reported positive topline outcomes from the Phase III study of subcutaneous pembrolizumab in conjunction with ...

The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...

Already a subscriber? Click the image to view the latest e-edition.

However, less than a quarter of patients (22.3%) had ever received treatment with pembrolizumab, and 10.7% had received lenvatinib in combination with pembrolizumab. Overall, 62.3% of patients ...

JERUSALEM, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, ...

US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...

Merck & Co. Inc.'s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck (MRK) said a trial of the drug, given ...

Merck's (MRK) new injectable version of Keytruda aims to overcome regulatory hurdles and market challenges, offering a more ...

Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...

Prosecutors are expected to wrap up their case in the trial against the man accused of killing Georgia nursing student Laken ...

Dozens of schools were closed and road and train travel ground to a halt as a cold snap brought snow, ice and sleet across ...

Through a first-of-its-kind report, the Canadian Mental Health Association (CMHA) is providing an in-depth look at the mental health system in Canada?with all its cracks and failings?and how people ...